$CGEN COM701 in combination with nivolumab ± BMS-986207 (anti-TIGIT) in heavily pretreated patient population, resulted in encouraging durable confirmed partial responses (overall response rate 20% (n=20) triple study, 10% (n=20) dual study and disease control rate (45%) for both), supported by immune activation with a favorable safety and toxicity profile Three of the patients responded to triplet therapy for at least 9 months as of the data cut-off date and all four triplet responders continue treatment Anti-tumor activity with confirmed partial responses reported in diverse histologies, with majority (5 out of 6 responders in the two combinations) in the hardest to treat high-grade serous adenocarcinoma histology which is typically less responsive to immune checkpoint inhibitors

$BDTX Black Diamond Therapeutics Inc. is cutting one of its cancer programs and laying off an undisclosed number of employees.

{$OBUV} у меня одного прогноз исчез ?